Changes in prescribing trends and initial pharmacotherapy of children with nocturnal enuresis in Japan: a large-scale medical claims database analysis
Tóm tắt
We analyzed the annual trends in and initial choice of pharmacotherapy for children with nocturnal enuresis (NE) using a large-scale medical claims database in Japan. A retrospective descriptive study performed using data from the Japan Medical Data Center between January 2005 and March 2019 involving 23,814 registrants under 16 years of age. In the first cohort of children with NE, we analyzed the comorbidities and associated annual pharmacotherapy prescribing trends. In the second cohort of only newly diagnosed cases, we analyzed the first prescribed age and initial choice of pharmacotherapy. A total of 3494 children with NE were identified (mean age, 5.1 ± 3.6 years; male, 66.0%). An incremental increase in the proportion of children administered NE medications was observed. The proportion of children treated with desmopressin significantly increased, whereas the prescription of tricyclic antidepressants significantly decreased and that of anticholinergics did not significantly change. Among the newly diagnosed children, 1897 were treated with approximately 90% of the prescribed monotherapy. Sublingual desmopressin monotherapy accounts for more than half of the initial pharmacotherapy from 2016 onward. Regardless of the drug class, pharmacological therapy was commonly initiated at the age of 8.3 ± 2.1 years. In Japan, the proportion of children treated with pharmacotherapy has been increasing. Furthermore, since the introduction of desmopressin sublingual formulations in 2012, a paradigm shift has occurred and this form of medication is now the most commonly prescribed, both from the annual perspective and as an initial choice among the newly diagnosed.
Tài liệu tham khảo
Kawauchi A, Naito Y, Iwasaki H, Miki T (2003) Epidemiology and pathophysiology of nocturnal enuresis. Jpn J Urol Surg 16:193–198
Fergusson DM, Horwood LJ, Shannon FT (1986) Factors related to the age of attainment of nocturnal bladder control: an 8-year longitudinal study. Pediatrics 78:884–890
Forsythe WI, Redmond A (1974) Enuresis and spontaneous cure rate. Study of 1129 enuresis. Arch Dis Child 49:259–263
Yeung CK, Sihoe JD, Sit FK, Bower W, Sreedhar B, Lau J (2004) Characteristics of primary nocturnal enuresis in adults: an epidemiological study. BJU Int 93:341–345
Van de Walle J, Van Herzeele C, Raes A (2010) Is there still a role for desmopressin in children with primary monosymptomatic nocturnal enuresis?: a focus on safety issues. Drug Saf 33:261–271. https://doi.org/10.2165/11319110-000000000-00000
The Guideline Committee of Japanese Society on Enuresis (2016) The clinical guideline for nocturnal enuresis 2016. Shindan-to-Chiryou-sha, Tokyo, pp 1–117 (in Japanese)
Neveus T, Eggert P, Evans J et al (2010) Evaluation of and treatment for monosymptomatic enuresis: a standardization document from the international children’s continence society. J Urol 183:441–447. https://doi.org/10.1016/j.juro.2009.10.043
Hjalmas K, Arnold T, Bower W et al (2004) Nocturnal enuresis: an international evidence based management strategy. J Urol 171:2545–2561. https://doi.org/10.1097/01.ju.0000111504.85822.b2
National Institute for Health and Clinical Excellence (2010) Nocturnal enuresis: the management of bedwetting in children and young people. https://www.nice.org.uk/guidance/cg111. Accessed 11 Nov 2020
Vilhardt H (1990) Basic pharmacology of desmopressin. Drug Invest 2:2–8
Robson WL, Leung AK, Norgaard JP (2007) The comparative safety of oral versus intranasal desmopressin for the treatment of children with nocturnal enuresis. J Urol 178:24–30. https://doi.org/10.1016/j.juro.2007.03.015
Medicines and Healthcare products Regulatory Agency (2007) Desmopressin nasal spray: removal of nocturnal enuresis indication, Drug Safety, update September 2007; pp 1–7. https://www.gov.uk/drug-safety-update/desmopressin-nasal-spray-removal-of-nocturnal-enuresis-indication. Accessed 11 Nov 2020
Hoffmann F, Glaeske G, Steuber C (2011) Did the removal of the indication of nocturnal enuresis for intranasal desmopressin change prescribing practice? Pharmacoepidemiol Drug Saf 20:105–109. https://doi.org/10.1002/pds.2070
NIHS Overseas Drug Safety Information. Natl Inst Health Sci 5(25): 9–11. http://www.nihs.go.jp/dig/sireport/weekly5/25071213.pdf. Accessed 11 Nov 2020
Medication leaflet: desmopressin intranasal 0.01% Kyowa. Pharmaceutical and Medical Devices Agency. http://www.pmda.go.jp/. Accessed 11 Nov 2020
Lottmann H, Froeling F, Alloussi S et al (2007) A randomised comparison of oral desmopressin lyophilizate (MELT) and tablet formulations in children and adolescents with primary nocturnal enuresis. Int J Clin Pract 61:1454–1460. https://doi.org/10.1111/j.1742-1241.2007.01493.x
Drugs interview form: MINIRINMELT® OD tablet 60μg/120μg/240μg. Pharmaceutical and Medical Devices Agency. http://www.pmda.go.jp/. Accessed 11 Nov 2020
Kimura S, Sato T, Ikeda S, Noda M, Nakayama T (2010) Development of a database of health insurance claims: standardization of disease classifications and anonymous record linkage. J Epidemiol 20:413–419. https://doi.org/10.2188/jea.je20090066
The Guideline Committee of Japanese Society on Enuresis: The clinical guideline for nocturnal enuresis 2004 (in Japanese). http://www.jsen.jp/guideline/guideline.pdf. Accessed 02 Feb 2021
Armitage P (1955) Tests for linear trends in proportions and frequencies. Biometrics 11:375–386
Spee-van der Wekke J, Hirasing RA, Meulmeester JF, Radder JJ (1998) Childhood nocturnal enuresis in The Netherlands. Urology 51:1022–1026
Tai HL, Chang YJ, Chang SC et al (2007) The epidemiology and factors associated with nocturnal enuresis and its severity in primary school children in Taiwan. Acta Paediatr 96:242–245. https://doi.org/10.1111/j.1651-2227.2007.00025.x
Joinson C, Heron J, Emond A, Butler R (2007) Psychological problems in children with bedwetting and combined (day and night) wetting: a UK population-based study. J Pediatr Psychol 32:605–616. https://doi.org/10.1093/jpepsy/jsl039
Lee SD, Sohn DW, Lee JZ, Park NC, Chung MK (2000) An epidemiological study of enuresis in Korean children. BJU Int 85:869–873
Bower WF, Moore KH, Shepherd RB, Adams RD (1996) The epidemiology of childhood enuresis in Australia. Br J Urol 78:602–606
Hoffmann F, Steuber C, Günther J, Glaeske G, Bachmann CJ (2012) Which treatments do children with newly diagnosed non-organic urinary incontinence receive? An analysis of 3188 outpatient cases from Germany. Neurourol Urodyn 31:93–98. https://doi.org/10.1002/nau.21177
Kaneko K (2012) Treatment for nocturnal enuresis: the current state in Japan. Pediatr Int 54:8–13. https://doi.org/10.1111/j.1442-200X.2011.03554.x
Ferrara P, Romano V, Cortina I, Ianniello F, Fabrizio GC, Chiaretti A (2014) Oral desmopressin lyophilisate (MELT) for monosymptomatic enuresis: structured versus abrupt withdrawal. J Pediatr Urol 10:52–55. https://doi.org/10.1016/j.jpurol.2013.05.021
EMEA Committee for Medicinal Products for Human Use (2006) Reflection paper: formulations of choice for the paediatric population. EMEA, London
Nevéus T (2011) Nocturnal enuresis-theoretic background and practical guidelines. Pediatr Nephrol 26:1207–1214. https://doi.org/10.1007/s00467-011-1762-8
Fonseca EG, Bordallo APN, Garcia PK, Munhoz C, Silva CP (2009) Lower urinary tract symptoms in enuretic and nonenuretic children. J Urol 182:1978–1983. https://doi.org/10.1016/j.juro.2009.04.083
Murray ML, de Vries CS, Wong IC (2004) A drug utilisation study of antidepressants in children and adolescents using the general practice research database. Arch Dis Child 89:1098–1102. https://doi.org/10.1136/adc.2004.064956
Swanson JR, Jones GR, Krasselt W, Denmark LN, Ratti F (1997) Death of two subjects due to imipramine and desipramine metabolite accumulation during chronic therapy: a review of the literature and possible mechanisms. J Forensic Sci 42:335–339
Butler RJ, Golding J, Heron J, ALSPAC Study Team (2005) Nocturnal enuresis: a survey of parental coping strategies at 7 1/2 years. Child Care Health Dev 31:659–667. https://doi.org/10.1111/j.1365-2214.2005.00556.x